Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| natural killer cell | 6 studies | 20% ± 3% | |
| CD16-positive, CD56-dim natural killer cell, human | 6 studies | 20% ± 4% | |
| epithelial cell | 4 studies | 32% ± 13% | |
| CD8-positive, alpha-beta memory T cell | 4 studies | 20% ± 3% | |
| gamma-delta T cell | 4 studies | 21% ± 5% | |
| T cell | 3 studies | 18% ± 3% | |
| conventional dendritic cell | 3 studies | 21% ± 5% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 16% ± 1% | |
| CD8-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
| dendritic cell | 3 studies | 24% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 1726.94 | 459 / 459 | 100% | 55.14 | 1118 / 1118 |
| esophagus | 100% | 2063.07 | 1445 / 1445 | 100% | 37.91 | 183 / 183 |
| intestine | 100% | 1919.61 | 966 / 966 | 100% | 36.09 | 527 / 527 |
| ovary | 100% | 2107.42 | 180 / 180 | 100% | 32.84 | 430 / 430 |
| prostate | 100% | 1929.69 | 245 / 245 | 100% | 29.52 | 502 / 502 |
| skin | 100% | 2349.21 | 1809 / 1809 | 100% | 39.55 | 472 / 472 |
| stomach | 100% | 1547.44 | 359 / 359 | 100% | 35.91 | 286 / 286 |
| uterus | 100% | 1890.48 | 170 / 170 | 100% | 41.72 | 459 / 459 |
| lung | 100% | 1675.00 | 577 / 578 | 100% | 38.20 | 1155 / 1155 |
| bladder | 100% | 1879.86 | 21 / 21 | 100% | 35.02 | 503 / 504 |
| brain | 100% | 1119.90 | 2629 / 2642 | 100% | 24.96 | 705 / 705 |
| thymus | 100% | 1658.98 | 653 / 653 | 99% | 20.68 | 599 / 605 |
| pancreas | 100% | 1073.79 | 328 / 328 | 99% | 28.54 | 176 / 178 |
| liver | 100% | 1172.96 | 226 / 226 | 98% | 21.34 | 399 / 406 |
| kidney | 100% | 1507.00 | 89 / 89 | 96% | 19.03 | 863 / 901 |
| adrenal gland | 100% | 1611.59 | 258 / 258 | 92% | 16.60 | 211 / 230 |
| adipose | 100% | 1679.07 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 1583.33 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 38.22 | 29 / 29 |
| spleen | 100% | 2165.74 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 36.14 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 15.46 | 1 / 1 |
| muscle | 99% | 826.78 | 798 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 99% | 21.24 | 79 / 80 |
| heart | 99% | 1020.10 | 849 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 98% | 2219.93 | 913 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0042254 | Biological process | ribosome biogenesis |
| GO_0005730 | Cellular component | nucleolus |
| GO_0005634 | Cellular component | nucleus |
| GO_0000175 | Molecular function | 3'-5'-RNA exonuclease activity |
| GO_0004527 | Molecular function | exonuclease activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0003723 | Molecular function | RNA binding |
| Gene name | ISG20L2 |
| Protein name | Interferon-stimulated 20 kDa exonuclease-like 2 (EC 3.1.-.-) |
| Synonyms | HSD38 HSD-38 |
| Description | FUNCTION: 3'-> 5'-exoribonuclease involved in ribosome biogenesis in the processing of the 12S pre-rRNA. Displays a strong specificity for a 3'-end containing a free hydroxyl group. . |
| Accessions | ENST00000313146.10 Q9H9L3 ENST00000368219.2 |